Surmodics (SRDX) to Release Quarterly Earnings on Wednesday

Surmodics (NASDAQ:SRDX - Get Free Report) is expected to issue its Q3 2025 quarterly earnings data before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $28.04 million for the quarter. Surmodics has set its FY 2025 guidance at -0.620--0.420 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). Surmodics had a negative return on equity of 7.10% and a negative net margin of 16.34%. The business had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Trading Up 12.3%

NASDAQ SRDX traded up $3.95 during mid-day trading on Friday, reaching $36.00. 519,340 shares of the stock were exchanged, compared to its average volume of 101,743. Surmodics has a one year low of $26.00 and a one year high of $41.77. The stock has a 50 day simple moving average of $29.90 and a 200-day simple moving average of $30.96. The stock has a market cap of $514.76 million, a P/E ratio of -25.90 and a beta of 1.31. The company has a debt-to-equity ratio of 0.27, a current ratio of 5.14 and a quick ratio of 3.99.

Institutional Investors Weigh In On Surmodics

An institutional investor recently raised its position in Surmodics stock. Millennium Management LLC raised its stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 71.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 206,487 shares of the company's stock after purchasing an additional 86,143 shares during the period. Millennium Management LLC owned 1.44% of Surmodics worth $6,304,000 as of its most recent SEC filing. Institutional investors own 96.63% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).